Skip to main content
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.
Published Web Location
http://europepmc.org/articles/PMC4381710?pdf=renderNo data is associated with this publication.
Abstract
In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.